Status:
COMPLETED
The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Prostate Cancer Metastatic
Eligibility:
MALE
50-85 years
Phase:
PHASE4
Brief Summary
Aim: The role of surgical castration and rosuvastatin treatment on lipid profile and lipid metabolism related markers was evaluated for their prognostic significance in metastatic prostate cancer (mPC...
Detailed Description
This prospective randomized controlled study was conducted at the National Cancer Institute (NCI), Cairo University. The study ID BB1901-30303 was approved by the Institutional Human Research Ethics C...
Eligibility Criteria
Inclusion
- Naïve newly diagnosed with metastatic prostate cancer
- Age ≥ 50 years.
- No psychological or geographical barriers for regular follow up of the patients.
Exclusion
- Age \< 50 years.
- psychological or geographical barriers for regular follow up of the patients.
Key Trial Info
Start Date :
January 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT04776889
Start Date
January 15 2019
End Date
December 30 2020
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute
Cairo, Egypt, 112796